Shares of Enzymotec Ltd. (NASDAQ:ENZY) traded down 6.1% on Tuesday . The stock traded as low as $7.42 and last traded at $7.42, with a volume of 62,240 shares trading hands. The stock had previously closed at $7.90.

Several analysts have recently weighed in on the stock. Jefferies Group reaffirmed a “hold” rating on shares of Enzymotec in a research note on Sunday, May 22nd. Zacks Investment Research downgraded shares of Enzymotec from a “hold” rating to a “sell” rating in a research note on Thursday, August 11th.

The company has a 50-day moving average price of $8.62 and a 200 day moving average price of $8.47. The firm has a market capitalization of $164.36 million and a P/E ratio of 26.85.

Enzymotec (NASDAQ:ENZY) last posted its quarterly earnings data on Tuesday, August 9th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by $0.04. During the same period in the previous year, the company posted $0.11 earnings per share. The firm had revenue of $15 million for the quarter, compared to analyst estimates of $14.90 million. Enzymotec’s revenue was down 12.7% on a year-over-year basis. On average, analysts forecast that Enzymotec Ltd. will post $0.29 EPS for the current fiscal year.

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.